IDEAYA Biosciences (IDYA) Stock Forecast, Price Target & Predictions
IDYA Stock Forecast
IDEAYA Biosciences stock forecast is as follows: an average price target of $46.13 (represents a 23.14% upside from IDYA’s last price of $37.46) and a rating consensus of 'Buy', based on 11 wall street analysts offering a 1-year stock forecast.
IDYA Price Target
The average price target for IDEAYA Biosciences (IDYA) is $46.13 based on 1-year price targets from 11 Wall Street analysts in the past 3 months, with a price target range of $68.00 to $18.00. This represents a potential 23.14% upside from IDYA's last price of $37.46.
IDYA Analyst Ratings
According to 11 Wall Street analysts, IDEAYA Biosciences's rating consensus is 'Buy'. The analyst rating breakdown for IDYA stock is 0 'Strong Buy' (0.00%), 10 'Buy' (90.91%), 1 'Hold' (9.09%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
IDEAYA Biosciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 10, 2024 | Ben Burnett | Stifel Nicolaus | $68.00 | $36.97 | 83.93% | 81.53% |
| Aug 27, 2024 | Yigal Nochomovitz | Citigroup | $58.00 | $39.80 | 45.73% | 54.83% |
| Aug 07, 2024 | Matthew Biegler | Oppenheimer | $53.00 | $35.86 | 47.80% | 41.48% |
| Jul 10, 2024 | Gregory Renza | RBC Capital | $61.00 | $37.33 | 63.41% | 62.84% |
| Jul 08, 2024 | Graig Suvannavejh | Mizuho Securities | $50.00 | $40.20 | 24.38% | 33.48% |
| Jun 03, 2024 | Ben Burnett | Stifel Nicolaus | $63.00 | $38.89 | 62.00% | 68.18% |
| Dec 28, 2022 | - | Capital One Financial | $29.00 | $17.47 | 66.00% | -22.58% |
| Sep 13, 2022 | - | Guggenheim | $32.00 | $12.40 | 158.06% | -14.58% |
| Aug 18, 2022 | - | Oppenheimer | $20.00 | $9.83 | 103.46% | -46.61% |
| Aug 16, 2022 | - | Robert W. Baird | $18.00 | $10.74 | 67.60% | -51.95% |
The latest IDEAYA Biosciences stock forecast, released on Sep 10, 2024 by Ben Burnett from Stifel Nicolaus, set a price target of $68.00, which represents a 83.93% increase from the stock price at the time of the forecast ($36.97), and a 81.53% increase from IDYA last price ($37.46).
IDEAYA Biosciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 2 | 5 | 6 |
| Avg Price Target | $63.00 | $58.00 | $58.83 |
| Last Closing Price | $37.46 | $37.46 | $37.46 |
| Upside/Downside | 68.18% | 54.83% | 57.05% |
In the current month, the average price target of IDEAYA Biosciences stock is $63.00, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 68.18% increase as opposed to IDEAYA Biosciences's last price of $37.46. This month's average price target is up 8.62% compared to last quarter, and up 7.09% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 27, 2024 | Citigroup | Buy | Buy | Hold |
| Aug 07, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Jul 10, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Jul 08, 2024 | BTIG | Buy | Buy | Hold |
| Jul 08, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Feb 21, 2024 | RBC Capital | Buy | Buy | Hold |
| Jan 25, 2024 | Goldman Sachs | Buy | Buy | Hold |
| Jan 10, 2024 | Wedbush | Buy | Buy | Hold |
| Sep 12, 2023 | Goldman Sachs | Buy | Buy | Hold |
| Dec 28, 2022 | Morgan Stanley | - | Equal-Weight | Initialise |
IDEAYA Biosciences's last stock rating was published by Citigroup on Aug 27, 2024. The company gave IDYA a "Buy" rating, the same as its previous rate.
IDEAYA Biosciences Financial Forecast
IDEAYA Biosciences Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $8.04M | $3.54M | $7.88M | $4.02M | $29.70M | - | $11.36M | $-38.02M | $24.98M | $8.76M | $7.25M | $10.57M | $8.97M | - |
| Avg Forecast | $38.39M | $23.96M | $7.40M | $3.96M | $11.79M | $3.55M | $4.10M | $4.67M | $5.75M | $4.34M | $4.46M | $5.43M | $8.84M | $8.38M | $4.89M | $6.14M | $7.00M | $6.64M | $7.69M | $6.71M | $8.98M | $8.55M | $14.24M | $7.48M | $7.92M | $70.56M | $100.00M |
| High Forecast | $38.39M | $23.96M | $7.40M | $3.96M | $11.79M | $3.55M | $4.10M | $4.67M | $5.75M | $5.26M | $4.46M | $5.43M | $17.39M | $8.38M | $4.89M | $6.14M | $7.00M | $6.64M | $7.69M | $9.25M | $12.38M | $11.79M | $19.65M | $10.32M | $10.93M | $97.32M | $137.93M |
| Low Forecast | $38.39M | $23.96M | $7.40M | $3.96M | $11.79M | $3.55M | $4.10M | $4.67M | $5.75M | $3.16M | $4.46M | $5.43M | $3.48M | $8.38M | $4.89M | $6.14M | $7.00M | $6.64M | $7.69M | $3.47M | $4.64M | $4.42M | $7.37M | $3.87M | $4.10M | $36.49M | $51.72M |
| # Analysts | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 3 | 6 | 10 | 9 | 9 | 8 | 8 | 4 | 3 | 6 | 4 | 6 | 4 | 6 | 4 | 6 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.96% | 0.72% | 1.28% | 0.57% | 4.47% | - | 1.69% | -4.23% | 2.92% | 0.61% | 0.97% | 1.33% | 0.13% | - |
IDEAYA Biosciences's average Quarter revenue forecast for Dec 23 based on 6 analysts is $8.84M, with a low forecast of $3.48M, and a high forecast of $17.39M. IDYA's average Quarter revenue forecast represents a 10.03% increase compared to the company's last Quarter revenue of $8.04M (Sep 23).
IDEAYA Biosciences EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 3 | 6 | 10 | 9 | 9 | 8 | 8 | 4 | 3 | 6 | 4 | 6 | 4 | 6 | 4 | 6 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-33.53M | $-32.71M | $-26.28M | $-26.44M | $1.58M | - | $-11.66M | $1.76M | $-29.92M | $-10.50M | $-8.64M | $355.87K | $-4.58M | $-12.05M |
| Avg Forecast | $-23.03M | $-14.38M | $-4.44M | $-2.38M | $-7.08M | $-2.13M | $-2.46M | $-2.80M | $-3.45M | $-2.60M | $-2.67M | $-3.26M | $-5.31M | $-5.03M | $-2.93M | $-3.69M | $-4.20M | $-31.82M | $-4.62M | $-17.32M | $-5.39M | $-28.93M | $-25.66M | $-8.32M | $-4.75M | $-8.86M | $-25.61M |
| High Forecast | $-23.03M | $-14.38M | $-4.44M | $-2.38M | $-7.08M | $-2.13M | $-2.46M | $-2.80M | $-3.45M | $-1.89M | $-2.67M | $-3.26M | $-2.09M | $-5.03M | $-2.93M | $-3.69M | $-4.20M | $-25.46M | $-4.62M | $-13.85M | $-2.79M | $-23.14M | $-20.53M | $-6.66M | $-2.46M | $-7.09M | $-20.49M |
| Low Forecast | $-23.03M | $-14.38M | $-4.44M | $-2.38M | $-7.08M | $-2.13M | $-2.46M | $-2.80M | $-3.45M | $-3.16M | $-2.67M | $-3.26M | $-10.44M | $-5.03M | $-2.93M | $-3.69M | $-4.20M | $-38.18M | $-4.62M | $-20.78M | $-7.43M | $-34.71M | $-30.79M | $-9.98M | $-6.56M | $-10.63M | $-30.73M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.67% | 11.14% | 7.13% | 6.30% | -0.05% | - | 0.67% | -0.33% | 1.03% | 0.41% | 1.04% | -0.07% | 0.52% | 0.47% |
8 analysts predict IDYA's average Quarter EBITDA for Dec 22 to be $-4.20M, with a high of $-4.20M and a low of $-4.20M. This is -364.98% lower than IDEAYA Biosciences's previous annual EBITDA (Sep 22) of $1.58M.
IDEAYA Biosciences Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 3 | 6 | 10 | 9 | 9 | 8 | 8 | 4 | 3 | 6 | 4 | 6 | 4 | 6 | 4 | 6 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-27.44M | $-27.93M | $-20.04M | $-21.96M | $2.57M | - | $-17.99M | $21.88M | $-31.55M | $-10.95M | $-9.02M | $-5.13K | $-4.93M | $-12.39M |
| Avg Forecast | $-63.54M | $-70.02M | $-77.67M | $-77.17M | $-55.35M | $-61.59M | $-55.35M | $-51.46M | $-50.04M | $-50.90M | $-41.76M | $-40.16M | $-36.46M | $-38.13M | $-43.02M | $-42.21M | $-43.27M | $-33.55M | $-37.94M | $-18.07M | $-20.30M | $-30.50M | $-26.74M | $-8.69M | $-19.53M | $-9.53M | $-25.90M |
| High Forecast | $-63.54M | $-70.02M | $-77.67M | $-77.17M | $-55.35M | $-61.59M | $-55.35M | $-51.46M | $-50.04M | $-42.42M | $-41.76M | $-40.16M | $-25.30M | $-19.46M | $-43.02M | $-42.21M | $-43.27M | $-26.84M | $-37.94M | $-14.46M | $-7.56M | $-24.40M | $-21.39M | $-6.95M | $-7.27M | $-7.63M | $-20.72M |
| Low Forecast | $-63.54M | $-70.02M | $-77.67M | $-77.17M | $-55.35M | $-61.59M | $-55.35M | $-51.46M | $-50.04M | $-59.38M | $-41.76M | $-40.16M | $-49.11M | $-59.93M | $-43.02M | $-42.21M | $-43.27M | $-40.26M | $-37.94M | $-21.68M | $-30.31M | $-36.60M | $-32.09M | $-10.42M | $-29.16M | $-11.44M | $-31.08M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.72% | 0.65% | 0.47% | 0.51% | -0.08% | - | 1.00% | -1.08% | 1.03% | 0.41% | 1.04% | 0.00% | 0.52% | 0.48% |
IDEAYA Biosciences's average Quarter net income forecast for Dec 22 is $-43.27M, with a range of $-43.27M to $-43.27M. IDYA's average Quarter net income forecast represents a -1783.57% decrease compared to the company's last Quarter net income of $2.57M (Sep 22).
IDEAYA Biosciences SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 3 | 6 | 10 | 9 | 9 | 8 | 8 | 4 | 3 | 6 | 4 | 6 | 4 | 6 | 4 | 6 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $7.86M | $7.08M | $6.30M | $5.75M | $6.67M | - | $5.92M | - | $14.83M | $4.83M | $4.82M | $3.80M | $3.94M | $3.99M |
| Avg Forecast | $32.05M | $20.01M | $6.18M | $3.31M | $9.85M | $2.97M | $3.42M | $3.90M | $4.80M | $3.62M | $3.72M | $4.54M | $7.38M | $7.00M | $4.08M | $5.13M | $5.84M | $5.55M | $6.42M | $6.65M | $7.50M | $7.14M | $11.79M | $4.64M | $6.62M | $7.62M | $8.35M |
| High Forecast | $32.05M | $20.01M | $6.18M | $3.31M | $9.85M | $2.97M | $3.42M | $3.90M | $4.80M | $4.39M | $3.72M | $4.54M | $14.52M | $7.00M | $4.08M | $5.13M | $5.84M | $5.55M | $6.42M | $7.97M | $10.34M | $9.85M | $14.15M | $5.57M | $9.13M | $9.15M | $10.02M |
| Low Forecast | $32.05M | $20.01M | $6.18M | $3.31M | $9.85M | $2.97M | $3.42M | $3.90M | $4.80M | $2.64M | $3.72M | $4.54M | $2.90M | $7.00M | $4.08M | $5.13M | $5.84M | $5.55M | $6.42M | $5.32M | $3.88M | $3.69M | $9.44M | $3.71M | $3.42M | $6.10M | $6.68M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.12% | 1.73% | 1.23% | 0.98% | 1.20% | - | 0.89% | - | 2.08% | 0.41% | 1.04% | 0.57% | 0.52% | 0.48% |
IDEAYA Biosciences's average Quarter SG&A projection for Dec 23 is $7.38M, based on 6 Wall Street analysts, with a range of $2.90M to $14.52M. The forecast indicates a -6.09% fall compared to IDYA last annual SG&A of $7.86M (Sep 23).
IDEAYA Biosciences EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 3 | 6 | 10 | 9 | 9 | 8 | 8 | 4 | 3 | 6 | 4 | 6 | 4 | 6 | 4 | 6 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.46 | $-0.00 | $-0.41 | $-0.46 | $0.06 | - | $-0.47 | $0.57 | $-0.31 | $-0.33 | $-0.28 | $-0.00 | $-0.17 | $-0.59 |
| Avg Forecast | $-0.81 | $-0.90 | $-1.00 | $-0.99 | $-0.71 | $-0.79 | $-0.71 | $-0.66 | $-0.64 | $-0.65 | $-0.54 | $-0.52 | $-0.47 | $-0.49 | $-0.55 | $-0.54 | $-0.55 | $-0.61 | $-0.51 | $-0.41 | $-0.31 | $-0.30 | $-0.07 | $-0.30 | $-0.30 | $2.93 | $1.83 |
| High Forecast | $-0.81 | $-0.90 | $-1.00 | $-0.99 | $-0.71 | $-0.79 | $-0.71 | $-0.66 | $-0.64 | $-0.54 | $-0.54 | $-0.52 | $-0.32 | $-0.25 | $-0.55 | $-0.54 | $-0.55 | $-0.61 | $-0.51 | $-0.15 | $-0.12 | $-0.11 | $-0.03 | $-0.11 | $-0.11 | $4.37 | $2.73 |
| Low Forecast | $-0.81 | $-0.90 | $-1.00 | $-0.99 | $-0.71 | $-0.79 | $-0.71 | $-0.66 | $-0.64 | $-0.76 | $-0.54 | $-0.52 | $-0.63 | $-0.77 | $-0.55 | $-0.54 | $-0.55 | $-0.61 | $-0.51 | $-0.61 | $-0.46 | $-0.45 | $-0.10 | $-0.44 | $-0.45 | $1.09 | $0.68 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.94% | 0.00% | 0.76% | 0.83% | -0.11% | - | 1.14% | -1.83% | 1.02% | 4.71% | 0.94% | 0.00% | -0.06% | -0.32% |
According to 8 Wall Street analysts, IDEAYA Biosciences's projected average Quarter EPS for Dec 22 is $-0.55, with a low estimate of $-0.55 and a high estimate of $-0.55. This represents a -969.87% decrease compared to IDYA previous annual EPS of $0.06 (Sep 22).
IDEAYA Biosciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VTYX | Ventyx Biosciences | $2.29 | $33.86 | 1378.60% | Buy |
| XFOR | X4 Pharmaceuticals | $0.71 | $3.67 | 416.90% | Buy |
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.60 | $7.00 | 169.23% | Buy |
| INZY | Inozyme Pharma | $6.00 | $14.67 | 144.50% | Buy |
| MGTX | MeiraGTx | $4.25 | $9.00 | 111.76% | Buy |
| SNDX | Syndax Pharmaceuticals | $19.12 | $36.00 | 88.28% | Buy |
| KROS | Keros Therapeutics | $56.98 | $105.00 | 84.28% | Buy |
| SWTX | SpringWorks Therapeutics | $37.42 | $67.33 | 79.93% | Buy |
| MLTX | MoonLake Immunotherapeutics | $51.14 | $79.33 | 55.12% | Buy |
| TERN | Terns Pharmaceuticals | $8.96 | $12.50 | 39.51% | Buy |
| AMLX | Amylyx Pharmaceuticals | $2.62 | $3.33 | 27.10% | Buy |
| IDYA | IDEAYA Biosciences | $37.46 | $46.13 | 23.14% | Buy |
| RNA | Avidity Biosciences | $41.71 | $50.00 | 19.88% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $43.70 | $51.20 | 17.16% | Buy |
| VRNA | Verona Pharma | $29.78 | $33.00 | 10.81% | Buy |
| VECT | VectivBio | $16.87 | $18.00 | 6.70% | Buy |
| PTGX | Protagonist Therapeutics | $47.02 | $50.00 | 6.34% | Buy |
| ANAB | AnaptysBio | $40.33 | $36.33 | -9.92% | Buy |
| CERE | Cerevel Therapeutics | $44.96 | $33.50 | -25.49% | Buy |
IDYA Forecast FAQ
Is IDEAYA Biosciences a good buy?
Yes, according to 11 Wall Street analysts, IDEAYA Biosciences (IDYA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 10 'Buy' recommendations, accounting for 90.91% of IDYA's total ratings.
What is IDYA's price target?
IDEAYA Biosciences (IDYA) average price target is $46.13 with a range of $18 to $68, implying a 23.14% from its last price of $37.46. The data is based on 11 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will IDEAYA Biosciences stock go up soon?
According to Wall Street analysts' prediction for IDYA stock, the company can go up by 23.14% (from the last price of $37.46 to the average price target of $46.13), up by 81.53% based on the highest stock price target, and down by -51.95% based on the lowest stock price target.
Can IDEAYA Biosciences stock reach $60?
IDYA's highest twelve months analyst stock price target of $68 supports the claim that IDEAYA Biosciences can reach $60 in the near future.
What is IDEAYA Biosciences's current price target trend?
2 Wall Street analysts forecast a $63 price target for IDEAYA Biosciences (IDYA) this month, up 68.18% from its last price of $37.46. Compared to the last 3 and 12 months, the average price target increased by 54.83% and increased by 57.05%, respectively.
What are IDEAYA Biosciences's analysts' financial forecasts?
IDEAYA Biosciences's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $24.12M (high $24.12M, low $24.12M), average EBITDA is $-14.473M (high $-14.473M, low $-14.473M), average net income is $-224M (high $-224M, low $-224M), average SG&A $20.14M (high $20.14M, low $20.14M), and average EPS is $-2.87 (high $-2.87, low $-2.87). IDYA's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $73.72M (high $73.72M, low $73.72M), average EBITDA is $-44.23M (high $-44.23M, low $-44.23M), average net income is $-288M (high $-288M, low $-288M), average SG&A $61.55M (high $61.55M, low $61.55M), and average EPS is $-3.699 (high $-3.699, low $-3.699).
Did the IDYA's actual financial results beat the analysts' financial forecasts?
Based on IDEAYA Biosciences's last annual report (Dec 2022), the company's revenue was $50.93M, beating the average analysts forecast of $28.04M by 81.61%. Apple's EBITDA was $-62.502M, beating the average prediction of $-57.951M by 7.85%. The company's net income was $-54.808M, missing the average estimation of $-133M by -58.74%. Apple's SG&A was $23.9M, missing the average forecast of $24.46M by -2.29%. Lastly, the company's EPS was $-1.32, missing the average prediction of $-2.077 by -36.46%. In terms of the last quarterly report (Sep 2023), IDEAYA Biosciences's revenue was $8.04M, missing the average analysts' forecast of $8.38M by -4.08%. The company's EBITDA was $-33.526M, beating the average prediction of $-5.028M by 566.82%. IDEAYA Biosciences's net income was $-27.44M, missing the average estimation of $-38.135M by -28.04%. The company's SG&A was $7.86M, beating the average forecast of $7M by 12.39%. Lastly, the company's EPS was $-0.46, missing the average prediction of $-0.489 by -5.96%